

and responsibilities, and their professional experience (curricula vitae should be supplied in appendices).

6. Understanding the Project Objectives (5 points)

The extent to which the applicant demonstrates an understanding of the rationale of active surveillance for pertussis, the importance of laboratory testing to confirm diagnoses, and the role of immunization registries in assessing vaccine-specific coverage and facilitating epidemiological studies.

7. Objectives (5 points)

The extent to which the applicant describes the surveillance area; documents a population of greater than 200,000 persons; and describes the demographic characteristics of the study population. The extent to which the surveillance population reflects that of the United States.

8. Human Subjects (Not Scored, However, an Application Can Be Disapproved if the Research Risks Are Sufficiently Serious and Protection Against Risks Is So Inadequate as to Make the Entire Application Unacceptable)

The application should also adequately address the requirements of 45 CFR part 46 for the protection of human subjects. This should include the provision of the FWA number from the Office of Human Research Projection (OHRP).

9. Budget (not scored)

The applicant shall describe their proposed plan for managing the resources necessary to comply with the requirements specified in Section D. This shall include a description of the proposed person hours for each key individual.

I. Other Requirements

Technical Reporting Requirements

The grantee will provide CDC with the original plus two copies of:

1. *Semi-annual progress reports.* The results of the measures of effectiveness shall be a data requirement to be submitted with or incorporated into the progress report.

2. Financial status report, no more than 90 days after the end of the budget period.

3. Final financial report and performance report, no more than 90 days after the end of the project period.

Send all reports to the Grants Management Specialist identified in the "Where to Obtain Additional Information" section of this announcement.

Additional Requirements

The following additional requirements are applicable to this program. For a complete description of each, see Attachment 1 of the announcement as posted on the CDC Web site.

AR-1—Human Subjects Requirements

AR-2—Requirements for Inclusion of Women and Racial and Ethnic Minorities in Research

AR-10—Smoke-Free Workplace Requirements

AR-11—Healthy People 2010

AR-12—Lobbying Restrictions

AR-14—Accounting System Requirements

AR-21—Small, Minority, and Women-Owned Business

AR-22—Research Integrity

Executive Order 12372 does not apply to this program.

J. Where To Obtain Additional Information

This and other CDC announcements, the necessary applications, and associated forms can be found on the CDC home page Internet address—<http://www.cdc.gov>.

Click on "Funding" then "Grants and Cooperative Agreements."

For general questions about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341-4146, Telephone: 770-488-2700.

For business management and budget assistance contact: Peaches Brown, Grants Management Specialist, Procurement and Grants Office, Centers for Disease Control and Prevention, 2920 Brandywine Road, Atlanta, GA 30341-4146, Telephone number: (770) 488-2738, E-mail address: PRB0@cdc.gov.

For program technical assistance, contact: Gregory S. Wallace, M.D., Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Mailstop E-61, Atlanta, GA 30333, Telephone number: (404) 639-8715, E-mail address: gsw2@cdc.gov.

Dated: April 30, 2003.

Edward Schultz,

Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 03-11138 Filed 5-5-03; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 03047]

Strengthening Blood Transfusion Services and Blood Safety in Tanzania; Notice of Availability of Funds

A. Authority and Catalog of Federal Domestic Assistance Number

This program is authorized under sections 301, 307, and 317 of the Public Health Service Act, (42 U.S.C. 241, 2421, and 247b), as amended. The Catalog of Federal Domestic Assistance number is 93.283.

B. Purpose

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 2003 funds for a grant program to design an appropriate approach for strengthening blood transfusion services and blood safety in Tanzania.

The purpose of the program is to assess key needs and resources and to make recommendations for strengthening blood supply and transfusion services in Tanzania. This program is being performed specifically in Tanzania according to U.S. Congressional mandate for Department of State, United States Agency for International Development (USAID) implementation in response to the 1998 bombing of the U.S. embassy in Tanzania.

On August 7, 1998, terrorists carried out nearly simultaneous bombings of the U.S. Embassies, which were located in a residential area of Dar Es Salaam, Tanzania, and in downtown Nairobi, Kenya. Taken together, these bombings had their intended terrorist and disastrous effect: the occurrence of a large number of premature deaths, disabling injuries, and post-traumatic psycho-social stress among the victims directly affected and among their families and co-workers. In addition to an enormous adverse impact on innocent people, the bombings caused substantial damage to property and also revealed widespread weaknesses in the disaster preparedness, management, and response capabilities, including blood transfusion services.

In October 1998, at the request of President Clinton and Dr. Donna Shalala, then Secretary of the U.S. Department of Health and Human Services (HHS), Surgeon General Dr. David Satcher and a team of experts traveled to Kenya and Tanzania. Dr.